225 related articles for article (PubMed ID: 16821591)
1. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.
Rino Y; Tarao K; Morinaga S; Ohkawa S; Miyakawa K; Hirokawa S; Masaki T; Tarao N; Yukawa N; Saeki H; Takanashi Y; Imada T
Anticancer Res; 2006; 26(3B):2221-6. PubMed ID: 16821591
[TBL] [Abstract][Full Text] [Related]
2. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
[TBL] [Abstract][Full Text] [Related]
3. High serum alanine aminotransferase levels for the first three successive years can predict very high incidence of hepatocellular carcinoma in patients with Child Stage A HCV-associated liver cirrhosis.
Miyakawa K; Tarao K; Ohshige K; Morinaga S; Ohkawa S; Okamoto N; Shibuya A; Adachi S; Miura Y; Fujiyama S; Miyase S; Tomita K
Scand J Gastroenterol; 2009; 44(11):1340-8. PubMed ID: 19891585
[TBL] [Abstract][Full Text] [Related]
4. Sustained low alanine aminotransferase levels can predict the survival for 10 years without hepatocellular carcinoma development in patients with hepatitis C virus-associated liver cirrhosis of child stage A.
Tarao K; Rino Y; Ohkawa S; Endo O; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Nagaoka T; Okamoto N; Tanaka K; Tarao N
Intervirology; 2004; 47(2):65-71. PubMed ID: 15192269
[TBL] [Abstract][Full Text] [Related]
5. Relationship between sustained elevation of serum alanine aminotransferase and progression from cirrhosis to hepatocellular carcinoma: comparison in patients with hepatitis B virus- and hepatitis C virus-associated cirrhosis.
Sato A; Kato Y; Nakata K; Nakao K; Daikoku M; Ishii N; Matsumoto T; Iseki K; Mazume H; Nagataki S
J Gastroenterol Hepatol; 1996 Oct; 11(10):944-8. PubMed ID: 8912132
[TBL] [Abstract][Full Text] [Related]
6. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
[TBL] [Abstract][Full Text] [Related]
7. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
Adachi S; Shibuya A; Miura Y; Takeuchi A; Nakazawa T; Saigenji K
Scand J Gastroenterol; 2008; 43(7):849-56. PubMed ID: 18584524
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.
Rodríguez-Díaz JL; Rosas-Camargo V; Vega-Vega O; Morales-Espinosa D; Mendez-Reguera A; Martínez-Tlahuel JL; Gamboa-Domínguez A; Arrieta O
Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):197-203. PubMed ID: 17359907
[TBL] [Abstract][Full Text] [Related]
9. Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma.
Mahmood S; Niiyama G; Kamei A; Izumi A; Nakata K; Ikeda H; Suehiro M; Kawanaka M; Togawa K; Yamada G
Liver Int; 2005 Apr; 25(2):220-5. PubMed ID: 15780042
[TBL] [Abstract][Full Text] [Related]
10. Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis.
Arrieta O; Rodriguez-Diaz JL; Rosas-Camargo V; Morales-Espinosa D; Ponce de Leon S; Kershenobich D; Leon-Rodriguez E
Cancer; 2006 Oct; 107(8):1852-8. PubMed ID: 16967451
[TBL] [Abstract][Full Text] [Related]
11. Overexpressed cyclo-oxygenase-2 in the background liver is associated with the clinical course of hepatitis C virus-related cirrhosis patients after curative surgery for hepatocellular carcinoma.
Morinaga S; Tarao K; Yamamoto Y; Nakamura Y; Rino Y; Miyakawa K; Ohkawa S; Akaike M; Sugimasa Y; Takemiya S
J Gastroenterol Hepatol; 2007 Aug; 22(8):1249-55. PubMed ID: 17688665
[TBL] [Abstract][Full Text] [Related]
12. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.
Pekow JR; Bhan AK; Zheng H; Chung RT
Cancer; 2007 Jun; 109(12):2490-6. PubMed ID: 17487861
[TBL] [Abstract][Full Text] [Related]
13. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
[TBL] [Abstract][Full Text] [Related]
14. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT.
Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kinjo F; Saito A; Yakabi S
Hepatogastroenterology; 2003; 50(49):165-9. PubMed ID: 12630015
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis.
Bozorgzadeh A; Orloff M; Abt P; Tsoulfas G; Younan D; Kashyap R; Jain A; Mantry P; Maliakkal B; Khorana A; Schwartz S
Liver Transpl; 2007 Jun; 13(6):807-13. PubMed ID: 17539001
[TBL] [Abstract][Full Text] [Related]
16. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
[TBL] [Abstract][Full Text] [Related]
17. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma?
Tanaka K; Sata M; Uchimura Y; Suzuki H; Tanikawa K
Oncol Rep; 1998; 5(1):205-8. PubMed ID: 9458323
[TBL] [Abstract][Full Text] [Related]
18. Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase.
Sánchez-Conde M; Berenguer J; Miralles P; Alvarez F; Carlos Lopez J; Cosin J; Pilar C; Ramirez M; Gutierrez I; Alvarez E
Clin Infect Dis; 2006 Sep; 43(5):640-4. PubMed ID: 16886160
[TBL] [Abstract][Full Text] [Related]
19. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis.
Aizawa Y; Shibamoto Y; Takagi I; Zeniya M; Toda G
Cancer; 2000 Jul; 89(1):53-9. PubMed ID: 10897000
[TBL] [Abstract][Full Text] [Related]
20. Is serum alanine transaminase level a reliable marker of histological disease in chronic hepatitis C infection?
Sanai FM; Benmousa A; Al-Hussaini H; Ashraf S; Alhafi O; Abdo AA; Alameri HF; Akbar HO; Bzeizi KI
Liver Int; 2008 Aug; 28(7):1011-8. PubMed ID: 18384520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
